The honeymoon phase: intersection of metabolism and immunology

@article{Aly2009TheHP,
  title={The honeymoon phase: intersection of metabolism and immunology},
  author={H. Aly and P. Gottlieb},
  journal={Current Opinion in Endocrinology, Diabetes and Obesity},
  year={2009},
  volume={16},
  pages={286–292}
}
  • H. Aly, P. Gottlieb
  • Published 2009
  • Medicine
  • Current Opinion in Endocrinology, Diabetes and Obesity
Purpose of reviewEven though the honeymoon phase in type 1 diabetes mellitus has been well known, its underlying pathogenic mechanisms remain poorly described. The common explanation that it occurs due to ‘β-cell rest’ on initiation of insulin therapy seems inadequate based on recent observations and studies and its underlying immunological aspects overlooked. Recent findingsIn this article, we will review the metabolic and immunological aspects of the honeymoon phase and we will present our… Expand
The Remission Phase in Type 1 Diabetes: Role of Hyperglycemia Rectification in Immune Modulation
TLDR
It is noteworthy that the interaction between glucose metabolism and immune plays an important role in the pathogenesis of the remission phase and the best intervention strategy may be the combination of strict glycemic control and immune modulation to protect β-cell function as early as possible. Expand
The honeymoon period repeatedly appears in two cases of type 1 diabetes mellitus
TLDR
Two cases that were diagnosed with type 1 diabetes mellitus and then underwent more than one honeymoon periods are presented. Expand
The honeymoon phase - what we know today about the factors that can modulate the remission period in type 1 diabetes.
TLDR
An up-to-date status on recent papers concerning remission in T1DM is given, as various clinical and metabolic factors have been analysed to assess whether they are influencing the remission rate and the duration of the honeymoon period. Expand
The remission phase in type 1 diabetes: Changing epidemiology, definitions, and emerging immuno‐metabolic mechanisms
TLDR
This review concentrates on the PR phase of T1DM to provide a comprehensive outlook of its epidemiology, diagnostic criteria, and underlying immune metabolic mechanisms. Expand
Remission Phase in Paediatric Type 1 Diabetes: New Understanding and Emerging Biomarkers
TLDR
This remission phase in childhood T1D could be a good checkpoint for the administration of future immunotherapies and finding those peripheral biomarkers that are signs of immunoregulation or islet regeneration could contribute to the identification of patients with a better glycaemic prognosis and a lower risk of secondary complications. Expand
Revisiting multiple models of progression of β‐cell loss of function in type 1 diabetes: Significance for prevention and cure
TLDR
New possible models for the natural history of the disease have been proposed and these models, in turn, may help facilitate fresh avenues for the prevention and cure of T1D. Expand
Influence of Vitamin D on Islet Autoimmunity and Beta-Cell Function in Type 1 Diabetes
TLDR
The current knowledge on the immunomodulatory effects of vitamin D is presented and the clinical interventional studies investigating its use for prevention or treatment of T1D are summarized. Expand
Hypothesis: an erythropoietin honeymoon phase exists.
TLDR
A new hypothesis that there may be an erythropoietin 'honeymoon phase' similar to that observed in diabetes mellitus is proposed, which could lead to less expensive and safer approaches to treatment of CKD anemia. Expand
Combination of vitamin D and dipeptidyl peptidase-4 inhibitors (VIDPP-4i) as an immunomodulation therapy for autoimmune diabetes.
TLDR
A comprehensive overview of the immunomodulatory properties of vitamin D and DPP-4 inhibitors, as well as the rationale for investigation of their combined use as an Immunomodulation therapy for autoimmune diabetes are provided. Expand
MicroRNAs: A Link Between Type 1 Diabetes and the Environment?
TLDR
Many miRNAs, and potentially other small regulatory RNA molecules discussed through this chapter, are involved in immune regulation and modulation, which may provide novel diagnostic, prognostic and therapeutic alternatives for Type 1 diabetes (T1D) in future. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 104 REFERENCES
The variable but inevitable loss of beta cells in overt type 1 diabetes
TLDR
The severity of clinical presentation of type 1 diabetes in children does not significantly influence the pattern of residual beta-cell function and longterm metabolic control, and the critical importance of a high index of suspicion and early diagnosis to prevent the development of ketoacidosis is highlighted. Expand
Immune intervention at diagnosis – should we treat children to preserve beta‐cell function?
TLDR
GAD vaccination has shown good results with impressive preservation of residual insulin secretion in 10‐ to 18‐year‐old type 1 diabetic patients with recent onset, and in patients with short diabetes duration at intervention the effect was remarkable and future studies will show whether the good effect seen so far can be confirmed. Expand
Effects of beta‐cell rest on beta‐cell function: a review of clinical and preclinical data
TLDR
The concept of ‘β-cell rest’, or suppression of insulin release from β-cells, was originally developed in the context of type 1 diabetes mellitus and was subsequently expanded into the field of type 2 diabetes, meaning that the agents used to induce β- cell rest may have many additional beneficial effects on glucose metabolism beyond their direct action onβ-cells. Expand
A Mini Meta‐Analysis of Studies on CD4+CD25+ T cells in Human Type 1 Diabetes
TLDR
A mini meta‐analysis is performed to compare the results in the four published studies, account for differences in their findings, and draw a consensus view on the role of this important cell subset in human T1DM. Expand
Role of regulatory T cells for the treatment of type 1 diabetes mellitus.
TLDR
It was demonstrated that Tregs recognizing beta-cell antigens are far more efficient in treating the disease than polyspecific T Regs, and could become an important weapon in the fight against immune mediated pathology. Expand
Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization
TLDR
The proposed Pre-POINT (Primary Oral/intranasal INsulin Trial) aims to identify an optimal insulin dose and route of application that is well tolerated and can induce an immune response to insulin for additional use in a phase II/III primary prevention trial in children at risk. Expand
The DPT‐1 trial: a negative result with lessons for future type 1 diabetes prevention
  • P. Pozzilli
  • Medicine
  • Diabetes/metabolism research and reviews
  • 2002
TLDR
The natural history of type 1 diabetes, at least in its final years before clinical onset, has been elucidated and reiterates the relevance of the present predictive tools (autoantibodies) for identifying individuals at risk for the disease. Expand
Regulatory T cells and type 1 diabetes.
TLDR
The therapeutic induction of regulatory T cells in prediabetic individuals carries great potential but is currently limited by the risks associated with deliberate generation of autoimmune responses that may exacerbate rather than ameliorate the autoimmune process. Expand
Type 1 diabetes as a relapsing–remitting disease?
TLDR
It is proposed that the immunological process that is at the root of T1D is relapsing–remitting in nature and the unresolved controversies and therapeutic implications of this hypothesis are discussed. Expand
Diabetes mellitus: Its differentiation into insulin‐sensitive and insulin‐insensitive types *
  • H. Himsworth
  • Medicine
  • Diabetic medicine : a journal of the British Diabetic Association
  • 2011
TLDR
In previous publications it has been shown that the efficiency with which insulin acts in the body is governed by an unknown factor or condition which renders the body sensitive both to injected and pancreatic insulin, and it was suggested that a type of diabetes mellitus might exist which was due, not to lack of insulin, but rather to loss of this sensitising factor. Expand
...
1
2
3
4
5
...